Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) and Windtree Therapeutics (NASDAQ:WINT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Insider and Institutional Ownership
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 0.5% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Sangamo Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sangamo Therapeutics | $176.23 million | 0.62 | -$257.83 million | ($1.47) | -0.36 |
| Windtree Therapeutics | N/A | N/A | -$20.29 million | ($143.89) | -0.03 |
Windtree Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Sangamo Therapeutics and Windtree Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sangamo Therapeutics | -146.30% | -82.17% | -56.21% |
| Windtree Therapeutics | N/A | -275.06% | -56.28% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Sangamo Therapeutics and Windtree Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sangamo Therapeutics | 0 | 3 | 3 | 0 | 2.50 |
| Windtree Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
Sangamo Therapeutics currently has a consensus price target of $5.67, indicating a potential upside of 976.29%. Given Sangamo Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Windtree Therapeutics.
Summary
Sangamo Therapeutics beats Windtree Therapeutics on 10 of the 12 factors compared between the two stocks.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
About Windtree Therapeutics
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitorfor the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
